NeuroVoices

Gus Alva, MD, DFAPA, medical director of ATP Clinical Research, commented on the potential clinical impact of AXS-05 for agitation in Alzheimer disease, caregiver burden, and the evolving collaboration between neurology and psychiatry.

In honor of Huntington Disease Awareness Month, held annually in May, the director of the Huntington's Disease Center at Northwestern Medicine discussed the design of the INVEST-HD trial.

The director of neurointerventional surgery at Abbott Northwestern Hospital, part of Allina Health, discussed evolving stroke care, patient selection, and emerging neurointerventional technologies shaping clinical practice.

The chief of neurology and director of Neuromuscular Medicine at Children’s Hospital of The King’s Daughters provided clinical insights on a number of SMA-related topics, including the recently approved high-dose nusinersen and the future of research and care.

Experts discussed new biomarker data from a phase 1/2 study, presented at the 2026 MDA Conference, of the gene therapy SGT-003 in boys living with Duchenne muscular dystrophy.

The division chief of neuroimmunology at Brigham and Women’s Hospital discusses longitudinal EBNA-1 antibody data and its potential role as a complementary biomarker to distinguish MS from related neuroinflammatory diseases.

The associate professor of neurology at Mayo Clinic provided a breakdown of the real-world eptinezumab data from INFUSE and its implications for early, robust migraine intervention after CGRP failure.

A duo of neuro-oncologists from Northwestern Medicine discussed how paraneoplastic neurologic syndromes differ from other cancer-related neurologic complications, highlighting key diagnostic challenges.

A nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.

The senior director of the Fluid Biomarker Program at Banner Health highlighted the evolving role of blood and fluid biomarkers in Alzheimer disease research and clinical practice.

A pair of pediatric epileptologists highlight the systemic and patient level factors driving inequities in infantile epileptic spasms syndrome care and outline paths toward more equitable diagnosis and treatment.

The neurosurgeon at Cleveland Clinic discussed the goals of the AES thalamic neuromodulation special interest group and the major clinical and research priorities shaping the future of neuromodulation for drug resistant epilepsy.

At CTAD 2025, the chief scientific officer at the Banner Alzheimer’s Institute discussed emerging antiamyloid therapies, clinical trial insights, and treatment duration in Alzheimer disease.

The pediatric epileptologist at Boston Children’s Hospital discussed national variability in treating infantile epileptic spasms syndrome and the evidence gaps that continue to shape clinical decision making.

At MDS 2025, the professor of neurology at Northwestern University Feinberg School of Medicine discussed the evolving landscape of disease-modifying clinical trials in Parkinson disease.

The vice president and Asset Head of Rare and Ultra-Rare Diseases at UCB provided clinical perspectives on the FDA approval of Kygevvi, the first marketed treatment specific for patients with thymidine kinase 2 deficiency (Tk2d).

The associate professor of physical medicine and rehabilitation at Virginia Commonwealth University discussed his passion for educating others about electrodiagnosis and ultrasound in neuromuscular disorders.

In honor of International Stuttering Awareness Day, the founder of the Stuttering Treatment and Research Society discussed understanding the diagnosis of stuttering and the importance of early intervention for patients.

The neurologist at University of British Columbia discussed how abnormal brain plasticity influences Parkinson progression and highlighted the importance of integrating basic science with clinical care.

The vice president of scientific engagement at the Alzheimer’s Association discussed the organization’s recently published first guidelines on blood-based biomarkers, highlighting accuracy, clinical use, and patient considerations.

The director of the Adult Genetic Epilepsy Program at the University of Toronto shared “back-to-school” guidance on best practices in helping young patients with epilepsy transition to adult care.

The VP of clinical development at Alkermes detailed phase 2 results for alixorexton, an oral, selective orexin 2 receptor agonist, in narcolepsy type 1, including benefits for fatigue, cognition, and weakness.

At AAIC 2025, the associate professor in the Department of Psychiatry at McGill University talked about the strengths and limitations of PET and blood biomarkers for Alzheimer disease. [WATCH TIME: 5 minutes]

The director of the Neuroethics Program at Cleveland Clinic discussed the evolving role of ethics in neurological clinical trials, highlighting skill development, safeguards, and patient-centered decision-making.

The head of the neurology department at Vall d’Hebron University Hospital provided clinical thoughts on fremanezumab’s expanded approval in pediatric migraine, the phase 3 SPACE study, and where future treatment may hold.

The Harold I. Nemuth Chair in Neurological Disorders at Virginia Commonweath University discussed the rationale, results, and future directions of GLP-1 RA therapy as a novel treatment strategy for idiopathic intracranial hypertension.

The cofounder and chief science officer of the Alzheimer's Drug Discovery Foundation recapped some of the notable recent developments in the Alzheimer disease field presented at the 2025 Alzheimer’s Association International Conference.

The associate professor in the Department of Psychiatry at McGill University discussed the strengths and limitations of PET and blood biomarkers in identifying early Alzheimer disease.